<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04150601</url>
  </required_header>
  <id_info>
    <org_study_id>SIMEOX-002</org_study_id>
    <nct_id>NCT04150601</nct_id>
  </id_info>
  <brief_title>Effects of SIMEOX on Flow and Volume in Healthy Subjects and Patients With COPD</brief_title>
  <official_title>Evaluation of SIMEOX Technology on Volumes and Flows Generated in Healthy Subjects and Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effects on the SIMEOX technology on flow and volume generated
      in healthy subjects and patients with COPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a crossover study assessing the immediate physiological effects of SIMEOX and a PEP
      device on the exhalation phase in healthy subjects and patients with COPD.

      Participants will perform (1) a slow vital capacity, (2) a maximal expiration from total lung
      capacity to residual volume with SIMEOX, (3) a maximal expiration from total lung capacity to
      residual volume with a PEP device.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in expiratory volume</measure>
    <time_frame>5 minutes</time_frame>
    <description>Expiratory volume change between the 3 conditions (spontaneous expiration, SIMEOX and PEP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in expiratory flow</measure>
    <time_frame>5 minutes</time_frame>
    <description>Expiratory flow change between the 3 conditions (spontaneous expiration, SIMEOX and PEP).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Spontaneous slow vital capacity</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have to perform a slow vital capacity according to the guidelines, from total lung capacity to residual volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIMEOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have to perform a passive exhalation using the SIMEOX, starting from total lung capacity and going until achieving residual volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have to perform an active exhalation using a PEP device, starting from total lung capacity and going until achieving residual volume</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SIMEOX</intervention_name>
    <description>SIMEOX is a device generating a succession of gentle depression at the mouth.</description>
    <arm_group_label>SIMEOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PEP</intervention_name>
    <description>A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.</description>
    <arm_group_label>PEP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Spontaneous Exhalation</intervention_name>
    <description>A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume</description>
    <arm_group_label>Spontaneous slow vital capacity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects: able to understand the instructions, no acute or chronic respiratory
             upper or lower airway disease, normal lung function.

          -  Patients with COPD: able to understand the instructions; FEV1&lt;80% predicted value,
             naive to the SIMEOX device.

        Exclusion Criteria:

          -  Healthy subjects: obesity (BMI &gt; 30kg/m²); active or former smoker; severe scoliosis;
             cardiovascular or neuromuscular disease.

          -  Patients with COPD: obesity (BMI &gt; 30kg/m²); severe scoliosis; cardiovascular or
             neuromuscular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>William Poncin, PT, PhD</last_name>
    <phone>+3227642316</phone>
    <email>william.poncin@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juliana RFF de Macedo, PT, MSc</last_name>
    <email>juliana.ribeiro@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <state>Brussels Capital</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Poncin</last_name>
      <phone>+320470592032</phone>
      <phone_ext>+320470592032</phone_ext>
      <email>william.poncin@uclouvain.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 31, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Poncin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

